A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multi-Centre Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 61
- 试验地点
- 1
- 主要终点
- Variation in Serum Levels of Follicle Stimulating Hormone (FSH)
研究概览
简要总结
This is a phase II, prospective, randomized, double-blind, placebo-controlled, international (Spain and Sweden) and multicentre study to explore the safety of 0.005% estriol vaginal gel in women with early stage breast cancer in treatment with Non-Steroidal Aromatase Inhibitors (NSAIs) in the adjuvant setting and symptoms of vaginal atrophy.
详细描述
This is a phase II, prospective, randomized, double-blind, placebo-controlled, international (Spain and Sweden) and multicentre study.
In the setting of postmenopausal hormone receptor positive breast cancer, treatment with aromatase inhibitors (AIs) is the most effective and well-studied therapy. Vaginal dryness is one of the most frequently reported symptom caused by this adjuvant therapy which may lead to a reduced adherence in breast cancer women.
This study will explore the safety of 0.005% estriol vaginal gel in this oncological context, to demonstrate that this medicinal product is a safe option to treat the vaginal atrophy caused by AIs, without a clinically relevant influence in gonadotropins or systemic estrogen levels.
The main objective is to evaluate the levels of Follicle Stimulating Hormone (FSH) after treatment with 0.005% estriol vaginal gel in hormone receptor-positive postmenopausal women with early stage breast cancer in treatment with Non-Steroidal Aromatase Inhibitors (NSAIs) in the adjuvant setting and symptoms of vaginal atrophy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Written informed consent prior to beginning specific protocol procedures.
- •Patients must have histological confirmation of breast adenocarcinoma with stage I-IIIA, documented at a local pathology department.
- •The breast tumors must be estrogen-receptor positive and/or progesterone receptor positive (≥1% of stained tumor cells by Immunohistochemistry (IHC) as determined by the local laboratory) with any Human Epidermal Growth Factor Receptor 2(HER2) status.
- •Postmenopausal status defined as: 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels > 40 Milli-international units per milliliter (mIU/ml) or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy.
- •Patient must be receiving the non-steroidal aromatase inhibitors anastrozole or letrozole as breast cancer treatment in the adjuvant setting for a minimum of 6 months.
- •Women suffering from moderate to severe vaginal dryness according to the FDA guidelines for drug development in postmenopausal women (Center for Drug Evaluation and Research, (CDER) Jan 2003). A moderate symptom will be considered if the symptom is present, bothersome and annoying, and a severe symptom will be considered if the symptom is present, bothersome and annoying, and interferes with the normal patient activity.
- •Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or
- •Adequate bone marrow as defined by the following laboratory values:
- •Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L.
- •Platelets (plt) ≥ 100 x 109/L.
- •Hemoglobin (Hgb) ≥ 10 g/dl.
- •Patient has adequate organ function as defined by the following laboratory values:
- •Serum creatinine ≤ 1.5 x Upper Limit of Normal (ULN).
- •Bilirubin ≤ 1.5 × ULN.
- •Alkaline phosphatase ≤ 2 × ULN.
- •Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 2 × ULN.
- •Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.
排除标准
- •Stage IIIB-IV breast cancer or bilateral breast cancer.
- •Treatment with any other current anti-tumoral therapy (chemotherapy, anti-Her2...etc) besides the NSAI. Pamidronate or Alendronate are permitted.
- •Prior history of other malignancy within 5 years of study entry, aside from non-melanoma skin cancer or carcinoma-in-situ of the uterine cervix adequately treated.
- •Postmenopausal uterine bleeding. Vaginal bleeding of unknown etiology.
- •Patients with endometrial thickness equal to or greater than 4 mm measured by transvaginal ultrasound.
- •Patients who have received any type of vulvovaginal treatment in the 15 days prior to the start of the study.
- •Use of any hormone, natural (phytoestrogens) or herbal products for the treatment of menopausal symptoms within the last 3 months.
- •Current or previous history of thromboembolic disease or coagulopathies.
- •Severe cardiovascular or respiratory diseases in the previous 6 months.
- •Renal Impairment.
- •Hepatitis B and/or hepatitis C carriers (unless with normal hepatic function).
- •Known human immunodeficiency virus infection.
- •Known hypersensitivity to NSAI.
- •Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
- •Previous investigational treatment for any condition or participation in any clinical trial within 4 weeks of inclusion date.
研究组 & 干预措施
0.005% estriol vaginal gel
Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
干预措施: estriol (Drug)
placebo vaginal gel
Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel. Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
干预措施: Placebo (Drug)
结局指标
主要结局
Variation in Serum Levels of Follicle Stimulating Hormone (FSH)
时间窗: from baseline to 12 weeks of treatment
Change from Baseline (mean screening-baseline) to Week 12 in Serum Levels of Follicle Stimulating Hormone (FSH) compare to natural physiological variability (screening-baseline variation)
次要结局
- Variation in Plasma Levels of Estrona(Change from baseline to week 1, week 3, week 8 and week 12)
- Variation in Serum Levels of FSH at Week 1, Week 3 and Week 8(Change from baseline to week 1, week 3 and week 8)
- Variation in Plasma Levels of Estradiol(Change from baseline to week 1, week 3, week 8 and week 12)
- Changes in Dryness of the Mucosa(week 3 and week 12 vs baseline)
- Variation in Plasma Levels of Estriol(Change from baseline to week 1, week 3, week 8 and week 12)
- Changes in Vaginal Dryness(week 3 and week 12 vs baseline)
- Changes in Vaginal Mucosa With Flattening of Folds or Thinning(week 3 and week 12 vs baseline)
- Changes in Dyspareunia(week 3 and week 12 vs baseline)
- Changes in Fragility of the Mucosa [Time Frame: Week 3 and Week 12 vs Baseline](from baseline to week 3 and 12)
- Variation in Serum Levels of Luteinizing Hormone (LH)(Change from baseline to week 1, week 3, week 8 and week 12)
- Changes in Vaginal pH Between Baseline and Week 3 and Week 12(week 3 and week 12 vs baseline)
- Change in Pruritus or Itching From Baseline to Week 3 and Week 12(Change from baseline to week 3 and week 12)
- Changes in Total Score of Symptoms of Vaginal Atrophy(week 3 and week 12 vs baseline)
- Changes in Vaginal Maturation Value(week 3 and week 12 vs baseline)
- Changes in Total Score of Signs of Vaginal Atrophy Between Week 3 and Week 12 to Baseline(week 3 and week 12 vs baseline)